Cor Vasa 2006, 48(7-8):267-271 | DOI: 10.33678/cor.2006.084
Facilitated percutaneous coronary intervention
- Kardio-Troll, Krajská nemocnice Pardubice, Pardubice, Česká republika
Presence of blood flow through the infarct-related artery prior to direct coronary angioplasty (percutaneous coronary intervention, PCI) is associated with a significantly better course of the disease. Several strategies of drug therapy instituted on first contact with the patient to recanalize an infarct-related artery before PCI have been proposed. Management with a full-dose fibrinolytic and management with a reduced-dose fibrinolytic combined with GP IIb/IIIa platelet receptor inhibitors prior to PCI demonstrably lead to a worse clinical course of acute myocardial infarction. While unfractionated heparin and acetylsalicylic acid continue to be the mainstay of current therapy, optimal drug therapy prior to PCI continues to pose a challenge to clinical research.
Keywords: Facilitated PCI; Direct PCI; Acute myocardial infarction; Thrombolysis
Published: July 1, 2006 Show citation
References
- Stone GW, Cox D, Garcia E. Normal TIMI (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001;104:636-41.
Go to original source... 
Go to PubMed... - Varvařovský I, Branny M, Černý J. Importance of the infarct related artery patency before primary angioplasty for acute myocardial infarction. Cor Vasa 2003; 45:579-82.
- O'Neill WW, Weintraub R, Grines CL. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-7. Go to original source... Go to PubMed...
- Vermeer F, Oude Ophuis AJ, van den Berg EJ. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999;82:426-31. Go to original source... Go to PubMed...
- Widimsky P, Groch L, Želízko M. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21:823-31. Go to original source... Go to PubMed...
- Ross AM, Coyne KS, Reiner JS. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34: 1954-62. Go to original source... Go to PubMed...
- Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569-78.
- ADVANCE MI Investigators. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 2005;150:116-22. Go to original source... Go to PubMed...
- Kastrati A, Mehilli J, Schlotterbeck K. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004;291:947-54. Go to original source... Go to PubMed...
- Ellis SG, Armstrong P, Betriu A. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 2004;147: E16. Go to original source... Go to PubMed...
- Montalescot G, Barragan P, Wittenberg O. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344: 1895-903. Go to original source... Go to PubMed...
- Montalescot G, Borentain M, Payot L. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004;292:362-6. Go to original source... Go to PubMed...
- Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006;367:579-88. Go to original source... Go to PubMed...
- The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial. JAMA 2006;295:e1-12. Go to original source... Go to PubMed...